Evidence map›Paper›PMID 37299583›Full record

ArticleNutrients2023

Assessment of the Efficacy of a Low-Dose Iron Supplement in Restoring Iron Levels to Normal Range among Healthy Premenopausal Women with Iron Deficiency without Anemia.

Matthew W Stefan, David M Gundermann, Matthew H Sharp, Brooke A Jennings, Raad H Gheith, Ryan P Lowery, Tieraona LowDog, Somsuvra B Ghatak, Jose Barbosa, Jacob M Wilson

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07263529 (Risk of Anemia Development and Clinical Effects of Oral Iron Therapy in Women), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07263529 narecruitingnot on this mapstarted 2025, after this paper: background citation

Risk of Anemia Development and Clinical Effects of Oral Iron Therapy in Women (18-55 Years) With Non-Anemic Iron Deficiency

TypeinterventionalSponsorIstanbul University - CerrahpasaRan2025 to 2026Enrolled60ConditionsNon-Anemic Iron DeficiencyArmsDietary Intervention (2 months), Oral Elemental Iron (Ferrous Sulfate) 80 mg/day
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Matthew W StefanThe Applied Science and Performance Institute, Research Division, Tampa, FL 33607, USA.
David M GundermannMegaFood, Manchester, NH 03103, USA.
Matthew H SharpThe Applied Science and Performance Institute, Research Division, Tampa, FL 33607, USA.ORCID 0000-0003-2018-9229
Brooke A JenningsThe Applied Science and Performance Institute, Research Division, Tampa, FL 33607, USA.
Raad H GheithThe Applied Science and Performance Institute, Research Division, Tampa, FL 33607, USA.
Ryan P LoweryThe Applied Science and Performance Institute, Research Division, Tampa, FL 33607, USA.
Tieraona LowDogMedicine Lodge Ranch, Pecos, NM 87552, USA.
Somsuvra B GhatakMegaFood, Manchester, NH 03103, USA.
Jose BarbosaMegaFood, Manchester, NH 03103, USA.
Jacob M WilsonThe Applied Science and Performance Institute, Research Division, Tampa, FL 33607, USA.

Funding

MegaFood N/A
6 · The paper itself

Abstract

(1) Background: Iron deficiency without anemia (IDWA) is a prevalent health concern in premenopausal women. Oral supplementation of iron may be a viable solution to improve blood-iron status in women; however, the effects of a high-dose iron-supplement regimen have been associated with gastrointestinal side effects. Therefore, the purpose of the present study was to evaluate the effectiveness of a low-dose liquid fermented iron-bisglycinate supplement (LIS) on improving blood-iron status in premenopausal women with IDWA without increasing constipation or gastrointestinal distress. (2) Methods: 85 premenopausal women with IDWA (ferritin < 70 ng/dL and hemoglobin > 11.0 g/dL) took a LIS (27 mg) or a placebo (PLA) for 8 weeks. Blood draws were taken at Wk0 and Wk8 of the study to measure serum-iron markers. In addition, surveys of gastrointestinal distress were administered at Wk0, Wk4, and Wk8 while the profile of mood states (POMS) was surveyed at Wk0 and Wk8. (3) Results: Compared to the placebo, the LIS was able to increase serum ferritin (

Indexed as

AnemiaAnemia, Iron-DeficiencyDyspepsiaGastrointestinal DiseasesIron DeficienciesFemaleFerritinsHemoglobinsHumansIronReference ValuesFerritinsHemoglobinsIronconstipationferritingastrointestinalironiron supplementlow ironWomen’s Health

Identifiers

PMID37299583
PMCPMC10255632
OpenAlexW4379470442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.